I just returned from the annual ISPOR show which showcases companies which tell the 'value' of a therapy coming to market ... thru a combination of "evidence synthesis, economic modeling or RWE (Real World Evidence) studies very smart people are able to create models which show the value - economic and medical for anything hitting the streets. This industry is reeling ... between the disruption w/in HHS, NIH, etc., the pricing EO, Medicare and UNH we are in a very real pivot at how Pharma/Health Care will be administered in the future. I don't think there is any going back.
My good friend, a 25 year pharma executive, told me this week this is the biggest disruption he has ever seen. Will the drugs and devices go away? Of course not, and they shouldn't ...will the crazy run these companies have been on happen again? Possibly. That being said, business models are being retooled as I type ...
Hence, the IBB chart below. Looks like it's sitting on a cliff of support and just finished a three way move up at the recent highs ... if/when we break the dashed red line of support, look at the near perfect BUY we have. That will...
49.5% of S&P 500 stocks are now in strong uptrends.
Here’s the chart:
Let's break down what the chart shows:
The blue line in the top panel shows the price of the S&P 500 index.
In green is the % of S&P 500 stocks above both their 200-day and their 50-day moving averages, indicating a longer-term uptrend.
In yellow is the % of S&P 500 stocks above their 200-day but below their 50-day moving averages. This indicates a longer-term uptrend but a short-term mess.
In red is the % of S&P 500 stocks below their 200-day and below their 50-day moving averages, indicating a longer-term downtrend.
The Takeaway: This chart does a good job of showing what’s really happening under the surface. And something just changed.
For 47 trading days, more S&P 500 stocks were trading below both their 200-day and 50-day moving averages. That trend had been in place for a while.
Like the rest of the All Star Charts team, I spent last week in New Orleans. It was hot. It was muggy. But the food—oh man, the food—made it all worth it.
I think I hit all the cornerstones of New Orleans cuisine:
I even enjoyed a non-alcoholic Hurricane. I was told it was a "Category 1". LOL
This trip was also a first for me: my first time visiting New Orleans sober. And let me tell you, it didn’t change my love for the city one bit. I still soaked in the music, the architecture, the culture, and that ever-present sense of celebration that pulses through every corner of the French Quarter.
But being clear-eyed did sharpen my awareness of some of the more absurd—and uniquely American—aspects of the experience. Lets just say I raised my eyebrow more than once at some of the things I observed...
The contrast was never more apparent than on the days we held our Portfolio Accelerator meetings in our hotel, right on Bourbon Street.
I have just returned to Kansas after spending a week in New Orleans with some of the brightest minds in finance at our Portfolio Accelerator event.
I had oysters for the first time, and they exceeded my expectations.
And I had my first hurricane, a drink that New Orleans is known for. They put way too much sugar and vodka in it... I don't think I'll try it again.
I also spent some time at the jazz bars where the music was incredible. My favorite was Pat O'Brien's Dueling Piano Bar, which I highly recommend you visit if you ever get the chance.
It was great to spend time with my Stock Market Media family.
Jason and Spencer were unable to attend, but everyone else was there. Mary, Alfonso, Steve, Sean, Grant, Rick, Louis, Patrick, Riley, and, of course, my loud and obnoxious Cuban friend, JC.
We also welcomed friends from around the world, and I’m incredibly grateful for the deep bench of talent and insight this community brings. It’s truly the best network in the business.
One highlight was hearing Brien Lundin speak Wednesday afternoon...
We’re back from New Orleans, so I’m doing a lot of catching up this weekend.
When I was plowing through charts yesterday, I realized two appeal to me a lot more than the rest right now.
One of the things I always do at Portfolio Accelerator is share my best ideas for the coming months and quarters.
I’ll share some tactical opportunities and discuss the themes and areas of the market I’m interested in trading.
But I’ll also zoom out and talk about some of the fresh new uptrends I’m buying with a longer timeframe in mind.
I’ve been an Asia bull for some time now. China has already been the best idea at past conferences. BABA, BIDU, and TCEHY are currently conviction longs for this theme.
Southeast Asia’s online retail giant, Sea Ltd $SE is another one I shared with our clients at one of last year’s events. It’s been a top international stock. It’s one of my largest long-term holdings...
The US Dollar Index $DXY continues to sit near the top of our macro checklist.
It’s been one of the more important tells of the cycle, not just for currencies—but for equities, commodities, and global risk assets.
Traditionally, the dollar moves opposite to US stocks. But as technicians, we know better than to marry intermarket correlations. These relationships ebb and flow, strengthen, weaken, invert, and sometimes go completely quiet. That’s normal.
Late last year, a big shift took place as stocks began to...
Below is my weekly video for members of Macke's Retail Roundup.
If a few weeks ago we had 'The Week From Hell" as I called it, then this week was "The Best Week Ever".
My Retail Roundup Portfolio ripping right now thanks to the changing market sentiment. And our newest position just had its second-best week as a public company.
So I'm in a great mood!
Below is my latest update on the portfolio, as well as a couple of new ideas for stocks that I could be interested in soon.
I talk all the time about how the options market makers are not stupid. Options are priced the way they are, when they are, because options market makers know what they are doing. Usually.
But once in a blue moon, they can get caught sleeping.
I think I may have found one such opportunity and I want to pounce on it today.
Our Hall of Famers list is composed of the 150 largest US-based stocks.
These stocks range from the mega-cap growth behemoths like Apple and Microsoft – with market caps in excess of $2T – to some of the new-age large-cap disruptors such as Moderna, Square, and Snap.
It has all the big names and more.
It doesn’t include ADRs or any stock not domiciled in the US. But don’t worry; we developed a separate universe for that. Click here to check it out.
The Hall of Famers is simple.
We take our list of 150 names and then apply our technical filters so the strongest stocks with the most momentum rise to the top.
Let’s dive right in and check out what these big boys are up to.
Here’s this week’s list:
*Click table to enlarge view
We filter out any laggards that are down -5% or more relative to the S&P 500 over the trailing month.
Every day, we sift through the filings to spot where the real conviction lies — cutting through the noise to highlight the most meaningful insider moves.
Here's what stood out today:
📌 Coupang $CPNG – Greenoaks Capital Partners bought $37.50 million in the ”Amazon of South Korea.”
It’s one of the biggest insider buys we’ve seen all year. Following the purchase, the firm now holds 55.2 million shares, representing about 3.66% of Coupang’s outstanding float among institutional holders.
From an early age, David Hale had hustle in his DNA. At just 10 years old, he was sneaking into casinos to play slot machines. By 11, he was betting on horse races. And before long, he was hunting for arbitrage opportunities in baseball card values. Inspired by his bargain-hunting mother, David developed a “value-player” mindset that would eventually spark a deep fascination with trading the markets.
It’s hard to believe Denise Shull is a product of parents and grandparents who believed in “buy and hold” and wouldn’t even know how to sell a share of stock if asked to.
Today, Denise is well known as a Performance Coach to big Wall Street traders, specializing in modern psychoanalysis.